ss ssss ss ssss ss ssss ss ssss ss ssss ss ssss ss ssss
questions and correctly well defined answers
ssss ss ssss ss ssss ss ssss ss ssss ss ssss ss
ssss latest already graded a+ 2025 – 2026
ss ssss ss ssss ss ssss ss ssss ss ssss ss ssss
1. How ss ssssdoes ss ssssthe ss ssss orbitofrontal ss ssss cortex ss ssss (OFC) ss ssss affect ss ssss the ss
amygdala?
ssss
ss ssss ANS inhibits ss ssss ss ssss andactivatess ss ssss the ss ssss amygdala
2. Wernicke's ss ssss area ss ssss is ss ssss associated ss sssswith which
ss ssss ss ssss of ss ssssthe ss ssss following?
ss ssss ANS speech compre-hension
ss ssss ss ssss s
3. The ss ssss limbic ss ssss system ss ssss is ss ssss associated ss ssss with which
ss ssss ss ssss of ss ssssthe ss
following
ssss
ss ssss ANS emotion ss ssss ss ssss andlearning s
4. Which ss ssss brain ss ssss structure ss ssss is most
ss ssss ss ssss associated ss ssss with ss ssss long ss
ssss term ss ssss memory? ss ssss ANS hip-pocampus ss ssss s
5. When ss ssss prescribing psychotropic
ss ssss ss ssss medications, the ss ssss ss ssss PMHNP ss
1 ss ssss/
ss ssss11
,ssss knows ss ssss that ss ssss thesemedications s ss ssss work ss ssss within ss ssss which ss ssss specific ss
ssss areas?
ss ssss ANS mood ss ssss
6. Which ss ssss of ss the
ssss ss ssss following ss ssssare ss ssssinvolved ss ssss in ss regulating
ssss s
neurotransmission via ex-citation-secretion coupling?
ssss ss ssss ss ssss s ssssss
ss ssss ANS voltage-sensitive sodium channels and voltage-sen-sitive
ss ssss ssssss ssssss ssssss ssssss s ss ssss calcium ss
ssss channels
7. What ss ssss system ss ssssinfluences ss ssss the ss ssss length ss ssssof time
ss ssss ss ssssfor ss ssss a drug
ss ssss to
ss ssss
ssssachieve ss ssss efficacy? ss ssss ANS - ss ssss
signal ss ssss transduction ss ssss cascades
8. One ss ssssof ss ssss the ss ssss signal ss ssss transduction ss ssss cascades, pass ss ssss ss ssss the ss
ssss message ss ssss from ss ssss a ss ssss firstreceptor s ss ssss to ss ssss a ss ssss second ss ssss messenger.
ss ssss ANS G ss ssss ss ssss protein ss ssss linked ss ssss systems
9. Human central ss ssss ss ssss nervous ss ssss system communication ss ssss ss ssss at synapses is
ss ssss ss ssss ss
which
ssss ss ssss of thefollowing?
ss ssss s
ss ssss ANS chemical ss ssss
10. Which ss ssss of ss ssss the ss ssss following ss ssss is ss ssss an ss ssss excitatory ss ssss neurotransmitter?
ss ssss ANS glutamate ss ssss
2 ss ssss/
ss ssss11
, 11. Which statement correctly pairs the pharmacodynamic effect
ss ssss ss ssss ss ssss ss ssss ss ssss ss ssss ss
ssss with its defi-nition?
ss ssss ss ssss s
ss ssss ANS antagonist effect - drug binds to receptor, but does not
ss ssss ss ssss ss ssss ss ssss ss ssss ss ssss ss ssss ss ssss ss ssss ss ssss ss
ssss activate a response ss ssss ss ssss
12. A ss ssss major ss sssscurrent ss ssss hypothesis for
ss ssss ss ssss the cause
ss ssss ss ssss of ss
ssss schizophrenia ss ssss proposes ss ssss thatN-methyl-d-aspartate
s ss ssss (NMDA) ss
ssss receptors ss ssss may ss ssss be ss ssss which ss ssss of ss ssss the ss ssss following? ss ssss Correct!
ss ssss ANS hypofunctional
ss ssss
13. Which ss ssss medication ss ssss is ss ssss least ss ssss associated ss ssss with ss ssss weight ss ssss gain?
ss ssss ANS aripiprazole ss ssss
14. Which ss ssss dopamine ss ssss pathway ss ssss is ss ssss associated ss ssss with ss ssss positive ss
ssss symptoms ss ssss of ss ssss schiz-ophrenia? s
ss ssss ANS mesolimbicss ssss ss ssss pathway
15. Which ss ssss pathway ss ssssis ss ssss associated ss ssss with ss ssss negative ss ssss symptoms?
ss ssss ANS The ss ssss ss ssss mesocorticalpathway s
16. Is ss ssss part ss ssss of the
ss ssss ss ssss extrapyramidal ss ssss nervous system
ss ssss ss ssss and ss
3 ss ssss/
ss ssss11